Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. 1998

G D Lowe, and J W Yarnell, and P M Sweetnam, and A Rumley, and H F Thomas, and P C Elwood
University Department of Medicine, Royal Infirmary, Glasgow, UK.

Plasma levels of fibrin D-dimer, tissue plasminogen activator (tPA) and plasminogen activator inhibitor (PAI) have been associated with ischaemic heart disease (IHD). However their associations with incident IHD in samples of the general population are not established. D-dimer antigen, tPA antigen and PAI activity were measured in stored, fasting plasma samples from 1,998 men aged 45-65 examined between 1984 and 1988, during the first re-examination of the Caerphilly Study cohort. These variables were related to major IHD events (myocardial infarction or IHD death) which occurred in 129 men during a follow-up period which averaged 61 months. Mean fibrin D-dimer was higher in men who developed IHD events (90 vs. 71 ng/ml; age-adjusted logarithmic mean difference 0.21; 95% CI 0.11, 0.30; p <0.0001). This association remained after adjusting for baseline IHD and for other risk factors including fibrinogen: the adjusted relative odds of IHD in the highest fifth of D-dimer were 3.5 (95% CI 1.8, 6.9; p = 0.0003). Mean tPA antigen was also higher in men who developed IHD (12.6 vs. 11.6 ng/ml; mean difference 0.9; 95% CI 0.2, 1.7; p = 0.02); however this difference largely disappeared after adjusting for other risk factors. PAI activity was not associated with risk of IHD.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D006113 United Kingdom Country in northwestern Europe including Great Britain and the northern one-sixth of the island of Ireland, located between the North Sea and north Atlantic Ocean. The capital is London. Great Britain,Isle of Man
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015849 Plasminogen Inactivators Important modulators of the activity of plasminogen activators. The inhibitors belong to the serpin family of proteins and inhibit both the tissue-type and urokinase-type plasminogen activators. Plasminogen Activator Inhibitor,Plasminogen Activator Inhibitors,Endothelial Plasminogen Activator Inhibitors,Placental Plasminogen Activator Inhibitors,Plasminogen Activator Inhibitors, Endothelial,Plasminogen Activator Inhibitors, Placental,Activator Inhibitor, Plasminogen,Inactivators, Plasminogen,Inhibitor, Plasminogen Activator,Inhibitors, Plasminogen Activator
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates

Related Publications

G D Lowe, and J W Yarnell, and P M Sweetnam, and A Rumley, and H F Thomas, and P C Elwood
June 1994, British heart journal,
G D Lowe, and J W Yarnell, and P M Sweetnam, and A Rumley, and H F Thomas, and P C Elwood
October 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology,
G D Lowe, and J W Yarnell, and P M Sweetnam, and A Rumley, and H F Thomas, and P C Elwood
May 1995, Atherosclerosis,
G D Lowe, and J W Yarnell, and P M Sweetnam, and A Rumley, and H F Thomas, and P C Elwood
May 2012, Stroke,
G D Lowe, and J W Yarnell, and P M Sweetnam, and A Rumley, and H F Thomas, and P C Elwood
April 2002, Arteriosclerosis, thrombosis, and vascular biology,
G D Lowe, and J W Yarnell, and P M Sweetnam, and A Rumley, and H F Thomas, and P C Elwood
August 1992, The Journal of biological chemistry,
G D Lowe, and J W Yarnell, and P M Sweetnam, and A Rumley, and H F Thomas, and P C Elwood
October 1987, Human nutrition. Applied nutrition,
G D Lowe, and J W Yarnell, and P M Sweetnam, and A Rumley, and H F Thomas, and P C Elwood
January 1994, European journal of clinical pharmacology,
G D Lowe, and J W Yarnell, and P M Sweetnam, and A Rumley, and H F Thomas, and P C Elwood
April 2016, Thrombosis research,
Copied contents to your clipboard!